Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, underscoring the company's robust financial health and operational efficiency.
The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions. This supports Knight's ongoing growth strategy across its pan-American pharmaceutical business. By repaying the debt ahead of schedule, Knight reduces its interest expenses and strengthens its balance sheet, positioning itself for future acquisitions or investments.
The repayment is significant because it demonstrates Knight's ability to generate sufficient cash from its core operations to meet large financial obligations. This is particularly important given the competitive and capital-intensive nature of the pharmaceutical industry. The company's focus on Canada and Latin America, through subsidiaries such as United Medical, Biotoscana Farma and Laboratorio LKM, has allowed it to tap into growing markets with increasing demand for pharmaceutical products.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products. The successful repayment may enhance investor confidence in the company's management and financial discipline. Moreover, the retained credit capacity provides flexibility for Knight to pursue strategic opportunities without immediate financing constraints.
The announcement also highlights the importance of the Paladin acquisition, which has contributed to Knight's revenue and cash flow. By integrating Paladin's portfolio, Knight has expanded its product offerings and market reach, particularly in Latin America. The strong cash flow generation suggests that the acquisition is delivering expected synergies and operational improvements.
For more details, the full press release is available at https://ibn.fm/8eluB. Additional information about Knight Therapeutics can be found on their website at www.knighttx.com.
